EGFR and mucoepidermoid carcinoma: Under such circumstances, there are several reports on the efficacy of the tyrosine-kinase inhibitor Gefitinib in patients with EGFR gene mutations [9,10], and this molecularly-targeted therapy is likely to improve prognoses of cases with progressive high-grade and recurrent MEC.